The first drug targeting the cause of Huntington’s disease was safe and well-tolerated in its first human trial led by UCL scientists. It successfully lowered the level of the harmful huntingtin protein in the nervous system.
After over a decade in pre-clinical development, this first human trial of huntingtin-lowering drug began in late 2015, led by Professor Sarah Tabrizi (UCL Institute of Neurology) and sponsored by Ionis Pharmaceuticals.
The trial involved enrolling 46 patients with early Huntington’s disease at nine study centres in the UK, Germany and Canada.
Each patient received four doses of either IONIS-HTTRx or placebo, given by injection into the spinal fluid to enable it to reach the brain. As the phase 1/2a trial progressed, the dose of IONIS-HTTRx was increased several times according to the ascending-dose trial design.
Patient safety was monitored throughout the study by an independent safety committee.
Today’s announcement at completion of the trial confirms that IONIS-HTTRx was well-tolerated by the trial participants and its safety profile supports further testing in patients.
Professor Tabrizi, Director of the UCL Huntington’s Disease Centre and IONIS-HTTRx Global Chief Investigator, said: “The results of this trial are of ground-breaking importance for Huntington’s disease patients and families. For the first time a drug has lowered the level of the toxic disease-causing protein in the nervous system, and the drug was safe and well-tolerated. The key now is to move quickly to a larger trial to test whether the drug slows disease progression.”
A major unknown was whether the trial would show that IONIS-HTTRx could lower the level of mutant huntingtin protein in the nervous system. Using an ultra-sensitive assay, concentrations of the protein were measured in each patient’s spinal fluid before and after treatment.
As hoped, IONIS-HTTRx produced significant, dose-dependent lowering of the level of mutant huntingtin – the first time the protein known to cause Huntington’s has been lowered in the nervous system of patients.
As a result of these successful outcomes, Ionis’ partner, Roche, has exercised its option to license IONIS-HTTRx and assumes responsibility for further development, regulatory activities and commercialization activities. Meanwhile, Ionis announced in June that all patients in the completed trial would be offered a place in an open-label extension to receive IONIS-HTTRx.
Learn more: Drug lowers deadly Huntington’s disease protein
The Latest on: Huntington’s disease
- Allie LaForce, Astros' Joe Smith talk to MLB Network about Huntington's disease charity on February 18, 2019 at 4:19 pm
Allie LaForce, Astros' Joe Smith talk to MLB Network about Huntington's disease charity Allie LaForce and Joe Smith have established a charity known as HelpCureHD Foundation to offer support for those ... […]
- In Pediatric Heart Disease: Understanding Post-Fontan Risks, Improving Parental Bonding, and Video Telemedicine on February 18, 2019 at 8:00 am
Cardiology 2019, the 22nd Annual Update on Pediatric and Congenital Cardiovascular Disease, occurred Feb. 13 to Feb. 17 in Huntington Beach. Organizers of the conference highlighted five finalists for ... […]
- Mt Kosciuszko on Torquay man Scott Ashworth’s bucket list in Huntington’s disease battle on February 16, 2019 at 5:28 pm
to tick a challenge off his bucket list. Scott Ashworth, 34, was once on the verge of a VFL umpiring berth and sports administration career, but has battled the deterioration of speech and movement as ... […]
- Astros reliever Joe Smith, wife continue battle against Huntington's disease on February 16, 2019 at 12:01 pm
Astros pitcher Joe Smith and wife, Allie LaForce at luncheon they hosted benefiting Help Cure HD. >>>See photos from the Astros' spring training in West Palm Beach, Fla., on Saturday, Feb. 16, 2019 .. ... […]
- New care framework for Huntington’s disease on February 16, 2019 at 2:04 am
One of the world’s first local Care Frameworks for Huntington’s Disease (HD) has been launched in Lothian. Families affected by HD joined health and social care partnership staff at the launch at Univ... […]
- Study: Diet drinks linked to higher rate of stroke, heart disease among women over 50 on February 15, 2019 at 4:58 pm
HUNTINGTON, W.Va. (WSAZ) -- It's an age-old debate -- diet ... drinking two or more diet sodas a day increases the risk for clot-based strokes and heart disease among women who are over the age of 50. ... […]
- Houston Astros pitcher, wife turn to IVF amid concerns of Huntington's disease on February 11, 2019 at 9:45 am
HOUSTON - Houston Astros pitcher Joe Smith and his wife, sports reporter Allie LaForce, are turning to in vitro fertilization to have a child because Smith's family carries the gene for Huntington's, ... […]
- Astros reliever Joe Smith hopes to help eliminate Huntington's disease through IVF foundation on February 11, 2019 at 8:18 am
Astros reliever Joe Smith has long dreamed of starting a family with his wife of four years, Allie LaForce, who is a basketball reporter for TNT. Only one thing has stopped them: Huntington’s ... […]
- Sports couple turns to IVF amid concerns of Huntington’s disease on February 11, 2019 at 6:02 am
Houston Astros pitcher Joe Smith and his wife, sports reporter Allie LaForce, talk to NBC’s Morgan Radford about their hopes to start a family with help from modern medicine. Joe’s family carries the ... […]
- Eli, The Straw man and Huntington disease on February 10, 2019 at 3:34 pm
When there's nothing you can do, sometimes it helps to do something. Anything. That's where Tam Maiuri's mind is as she watches her mother live and struggle with Huntington disease, a genetic disorder ... […]
via Google News and Bing News